Thyroid dysfunction is common in newborn infants with Down's syndrome (DS) but defects in organogenesis have not been described. A female infant was diagnosed to have trisomy 21, atrio-ventricular septal defect and patent ductus. Newborn screening showed capillary TSH 43.8 mU/L(day 5), venous TSH >150 mU/l and free T4 15.1 pmol/L (day 12). Thyroid ultrasound showed a small gland with heterogenous echotexture and cystic changes. Scintigraphy showed normal uptake into an eutopic gland. The infant was treated with thyroxine and underwent cardiac repair at 69 days. Sequencing analysis of candidate genes involved in thyroid development revealed a new heterozygous mutation close to the transcription initiation site of the PAX8 gene. Electromobility shift assay (EMSA) studies exhibited that the sequence at this position is not involved in specific protein binding. However, the mutant PAX8 promoter showed a significantly reduced transcriptional activation of a luciferase reporter gene in vitro tested in HEK, PCCL3 as well as in HeLa cells indicating that the mutation is very likely to lead to a reduced PAX8 gene expression. Further study in infants with DS and TSH elevation are indicated to investigate whether or not there is a true association between DS and PAX8 mutations.
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